Immunotherapy combo shows promise against aggressive kidney cancer

NCT ID NCT05148546

Ongoing Disease control Sponsor: The Netherlands Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests three different immunotherapy combinations given before surgery to patients with high-risk clear cell kidney cancer. The goal is to see if these drugs can shrink the tumor and reduce the risk of the cancer returning. About 69 participants will receive either nivolumab alone, nivolumab plus ipilimumab, or nivolumab plus relatlimab, followed by surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab, ipilimumab, and relatlimab (immunotherapy drugs)
What this could lead to: If successful, this could lead to a new treatment approach that lowers the chance of kidney cancer coming back after surgery.
What could go wrong: This is an early phase II trial with only 69 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects like inflammation of organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nonpapillary renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL CELL CARCINOMA

Contacts and locations

Locations

Netherlands Cancer Institute

Amsterdam, North Holland, 1066CX, Netherlands
Royal Free London NHS Foundation Trust

London, NW3 2QG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.